Endocyte (ECYT) Posts Narrower-than-Expected Q4 Loss

Endocyte (NASDAQ: ECYT) reported Q4 EPS of ($0.19), $0.06 better than the analyst estimate of ($0.25).

The Company expects that its cash balance at the end of 2015 will exceed $155 million. Spending is expected to increase from the first half of 2015 to the second half as the trials for EC1456 and EC1169 are expanded once the maximum tolerated doses are determined.

For earnings history and earnings-related data on Endocyte (ECYT) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Five Below (FIVE) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY27 Guidance
• PVH Corp. (PVH) Tops Q1 EPS by 19c, Offers Guidance